Background: A low 25-hydroxyvitamin D3 (25(OH)D3) serum concentration at melanoma diagnosis
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The pro-hormone vitamin D (vitD) has pleiotropic actions on human cells, including some that are relevant to cancer, notably on cell growth, differentiation or apoptosis, or on the immune system. VitD is mainly synthetized in the skin during ultraviolet-exposure or, to a lesser extent, is ingested from some foods or supplements. It is mainly transported to target cells after hydroxylation to 25 hydroxyvitaminD3 (25(OH)D3), which is believed to represent its reservoir form. 25(OH)D3 acts after transformation in target cells into active compounds, the main being 1-25(OH)2D3, through interaction with the vitD receptor (1) . Several prospective population-based studies have shown higher 25(OH)D3 serum levels statistically significantly associated with decreased risk of later diagnosis of breast (2) , colon (3), renal (4) , hepatocellular (5), or tobacco-related cancers (6) . However, randomized intervention studies of vitD supplementation failed to demonstrate any reduction of cancer development (7) , suggesting a reverse causation association between low 25(OH)D3 serum levels and presence of cancer.
Several cohort studies have shown statistically significant associations between low 25(OH)D3 serum levels at diagnosis and presence of poor prognosis criteria, decreased cancer-specific or overall survival (OS) in patients with colon (8) , breast (2, 9) , prostate (10), bladder (11) , or all cancers (7, 12) .
However, when multivariate adjustments with other prognostic criteria, cancer therapy, or body mass index (BMI) were made, the association vanished, as for breast cancer (13) . Few study investigated the prognostic value of variations of 25(OH)D3 serum level during follow-up of cancer patients. Postdiagnosis vitD intake or high 25(OH)D3 serum level were not associated with any improvement of allcause or disease-specific mortality in prospective cohorts of colon (14) , breast (13) , or prostate (15) cancer patients. Similarly, no impact of vitD supplementation was demonstrated on prostate specific antigen level in black men with prostate cancer (16) .
Cutaneous melanoma is a severe cancer once spread to distant organs, with main prognostic factors being Breslow's thickness, ulceration and mitotic rate of the primary lesion and status of the draining lymph nodes (17) . In vitro studies have shown growth inhibition of malignant melanoma cell lines by 1,25(OH)2D3 (18) . In patients with newly diagnosed melanoma, low 25(OH)D3 serum level was associated with worse prognostic factors, such as Breslow's thickness (19) , higher American Joint committee on cancer (AJCC) melanoma stage (20) and with worse survival independently of Breslow's thickness in one prospective study (21) .
Studies on 25(OH)D3 and cancer occurrence or prognosis were often flawed by various biases, such as lack or incomplete handling of factors that control its serum level, like seasonality of blood drawing, body mass index (BMI), age, and sex. In addition, no study ever evaluated the prognostic role of 25(OH)D3 serum level measured during the follow-up of melanoma patients. We aimed, using a prospective cohort of melanoma patients with multiple assessment of 25(OH)D3 serum levels and where most factors that control 25(OH)D3 serum levels were recorded, 1)to confirm the prognostic value of 25(OH)D3 serum level collected at diagnosis and, 2)for the first time, to evaluate whether changes during follow-up of 25(OH)D3 serum levels could be associated with modifications of disease free survival (DFS) or OS.
Patients and methods

Study population
MelanCohort has been described previously (22) . Briefly, a cohort of adults diagnosed with skin melanoma was set up from great Paris university hospitals (APHP) between September 2003 and December 2008 and followed-up prospectively. Cases had confirmed melanoma by central pathology review and were included within 3 months after curative surgery of primary melanoma or of invaded 6 nodes or within one month after diagnosis of distant metastasis. This study was registered in ClinicalTrials.gov database (NCT00839410). All patients gave written informed consent and ethical committee CPP IDF 8 approved study. Follow-up visits were recorded prospectively every two visits required by the French Guidelines (twice yearly for stage I patients, 4 times yearly for stage II-III) (23) .
Melanoma prognostic criteria were collected prospectively (Breslow thickness, ulceration, nodal status, mitotic rate, age, sex, location of the primary, AJCC stage). At inclusion and during prescheduled followup visits, blood was drawn and serum samples were aliquoted and stored at -80 Celsius degrees in centralized biobank. Using central APHP Diagnosis Related-Groups system, we estimated that roughly 50% of melanoma patients presenting to APHP during study period were included in MelanCohort. For this study, we analyzed patients with only one invasive melanoma. 25(OH)D3 serum level was measured, blinded to clinical information, by mass spectrometry coupled to high-performance liquid chromatography, with a precision of 5%, and expressed as nmol/L (see Supplementary Methods).
Statistical methods
To enable comparisons of survival according to serum level of 25(OH)D3 (initial value at diagnosis and values recorded during follow-up), we produced standardized 25(OH)D3 levels adjusted for month of sampling, age, sex, and BMI, using a generalized linear model restricted to patients for whom 25(OH)D3 was measured within 6 months after primary melanoma diagnosis (Fig 1, supplementary Table 2 ). The sensitivity analysis was also conducted by AJCC stage groups Table 5 ). This analysis, for which only individuals with similar number of tests are compared in each stratum, resulted in similar results as the main analysis.
Analyses performed on OS yielded similar results, with no effect of baseline 25(OH)D3 on survival, but changes of 25(OH)D3 through time associated with worse prognosis (Supplementary Table 6 ).
Characteristics of individuals who experienced an important increase or decrease of 25(OH)D3
serum levels with time are given in Supplementary Figure 4 shows the HR on the risk of relapse for the same Cox model using Breslow's thickness either as a continuous variable, i.e. linear parameter, or as a categorical variable to account for non-linearity.
Discussion
The analysis of 25(OH)D3 serum level in this prospective cohort of carefully followed-up melanoma patients enabled us to confirm already described association between low 25(OH)D3 serum level at diagnosis and prognostic factors, such as higher Breslow's thickness (19) or higher AJCC melanoma stage (20) and, to the best of our knowledge for the first time, to investigate the role of its variations during follow-up. As expected by the associations at diagnosis, in crude analysis, low 25(OH)D3 levels were associated with poorer DFS and OS. However, as soon as proper adjustments were used for prognostic 12 factors such as AJCC stage, or stratifying the analysis on prognostic markers, this association totally disappeared. Thus, in our study, 25(OH)D3 serum level at diagnosis was not an independent melanoma prognostic marker.
These results strongly differ from J Newton-Bishop et al (21) ones. Our analysis showed that a statistically significant association could be evidenced only when poorly accounting for prognostic factors, such as in unadjusted analysis or when using Breslow's thickness as a continuous variable. Noteworthy, our study had some methodological advantages: it followed the REMARK guidelines for tumor markers in prognostic studies (25) , patient losses to follow-up were limited, serum samples were carefully handled and 25(OH)D3 serum levels were measured by mass-spectrometry, considered as the most accurate method (26) . Some widely used techniques of 25(OH)D3 serum level measurement are easier, but are hampered by high inter-method variability (26) . Our method of standardization of 25(OH)D3 serum level used adjustments to the main factors that influence its level in the normal population (27) . Although we cannot exclude that unmeasured confounders biased our results, we believe this method of standardization as accurate.
Although the baseline value of standardized 25(OH)D3 serum level was not an independent prognostic marker, its variation through time was. The use of time-dependent variables as a prognostic marker is always a limitation because potential bias could arise, such as reverse causation. Our analysis did not indicate evidence of reverse causation in the analysis of changes in 25(OH)D3 serum level.
Because of our careful standardization of 25(OH)D3 serum level, we think this result valuable.
Noteworthy, a U-shaped association between 25(OH)D3 serum levels at diagnosis and prognosis has been shown for prostate cancer, with both high and low levels at diagnosis being associated with higher grade disease (28) .
The biological significance of our finding on the prognostic value of changes in 25(OH)D3 levels overtime is unclear. Decrease in 25(OH)D3 levels upon time may be associated with inflammation, and serum concentrations of tumor necrosis factor-α or C-reactive protein have been repeatedly reported inversely correlated with 25(OH)D3 concentrations (7) . Driver mutations in melanoma cells increase secretion of pro-inflammatory cytokines such as interleukin-6 and -8 and there is also evidence that ulceration of the primary lesion, a potent poor prognostic factor for melanoma, is associated with inflammation (29) . Alternatively, progression is associated with poorer global health, thus limiting sunexposure, the main source of vitD. It is more difficult to understand the cause of increase of 25(OH)D3
upon time. VitD3 supplementation may be an explanation, but we did not recorded prospectively use of vitD supplements. However, we measured vitD2 levels, a method of vitD supplementation used in
France, and failed to show that vitD2 supplementation had any impact on variation over time of 25(OH)D3 levels. Nevertheless, we cannot exclude that some patients ingested vitD3 as supplements, nor did we measured patients' expositions to the sun. In fact, all patients were instructed to refrain from exposing their skin to the sun. Our results do not also favor the hypothesis that vitD might mediate the reported lowered risk of relapse for melanoma patients who have sunny holidays after melanoma diagnosis (30) .
Because, a change of 25(OH)D3 serum level upon time in both directions was associated with worse prognosis in melanoma patients, it is unlikely a direct consequence of vitD biological actions. We 
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